Compare LII & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LII | HOLX |
|---|---|---|
| Founded | 1895 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Electronics |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 16.6B |
| IPO Year | 1999 | 1995 |
| Metric | LII | HOLX |
|---|---|---|
| Price | $564.64 | $75.45 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 13 |
| Target Price | ★ $595.92 | $77.89 |
| AVG Volume (30 Days) | 483.3K | ★ 2.3M |
| Earning Date | 04-29-2026 | 04-27-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 1.11 | N/A |
| EPS | ★ 22.79 | 0.79 |
| Revenue | ★ $5,195,300,000.00 | $4,100,500,000.00 |
| Revenue This Year | $6.90 | $4.74 |
| Revenue Next Year | $5.69 | $5.03 |
| P/E Ratio | ★ $25.03 | $95.34 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $443.19 | $51.90 |
| 52 Week High | $689.44 | $75.49 |
| Indicator | LII | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 62.78 |
| Support Level | $536.57 | $74.53 |
| Resistance Level | $573.81 | N/A |
| Average True Range (ATR) | 18.50 | 0.21 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 74.11 | 96.67 |
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.